Curtana Pharmaceuticals Market Research Report

Background

Company Overview

Curtana Pharmaceuticals is a privately held, preclinical-stage biopharmaceutical company founded in 2013 and headquartered in Austin, Texas. The company specializes in developing first-in-class, small molecule therapeutics targeting cancer stem cells in the central nervous system, focusing primarily on glioblastoma (GBM) and medulloblastoma (MB). Their lead candidate, CT-179, is designed to inhibit the OLIG2 transcription factor, which plays a critical role in tumor initiation and growth.

Mission and Vision

Curtana Pharmaceuticals aims to revolutionize the treatment of aggressive brain cancers by developing highly targeted therapies that address the root causes of tumor growth and resistance. Their vision is to improve survival rates and quality of life for patients with GBM and MB through innovative, precision medicine approaches.

Industry Significance

The company holds a significant position in the biopharmaceutical industry by focusing on the unmet needs of brain cancer treatment. With limited effective therapies available, Curtana's targeted approach offers promising prospects for advancing treatment options in this challenging field.

Key Strategic Focus

Core Objectives

• Development of Targeted Therapies: Focus on creating small molecule inhibitors that specifically target cancer stem cells in the central nervous system.

• Advancement of CT-179: Progress CT-179 through clinical trials to establish its safety and efficacy in treating GBM and MB.

Areas of Specialization

• Cancer Stem Cell Targeting: Developing therapies that specifically target cancer stem cells to prevent tumor recurrence and resistance.

• Central Nervous System Oncology: Specializing in brain cancers, particularly glioblastoma and medulloblastoma.

Key Technologies Utilized

• OLIG2 Inhibition: Utilizing small molecule inhibitors to block the OLIG2 transcription factor, which is essential for tumor initiation and growth in certain brain cancers.

Primary Markets Targeted

• Glioblastoma (GBM): Affecting adults, with a median survival of less than 15 months and a five-year survival rate of less than 10%.

• Medulloblastoma (MB): Affecting children, with recurrence rates of 30-40% and a five-year survival rate of about 25% after recurrence.

Financials and Funding

Funding History

• 2014: Awarded a $7.6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

• 2017: Received an investment from angelMD, marking the first new syndicate completed in 2017.

Total Funds Raised

Approximately $7.6 million in grants and investments.

Recent Funding Rounds

• February 2017: Investment from angelMD.

Notable Investors

• Thynk Capital

• angelMD

• Biosense Global

• DEFTA Partners

Intended Utilization of Capital

The funds are primarily allocated towards advancing the development of CT-179, including preclinical studies, clinical trial preparations, and regulatory submissions.

Pipeline Development

Key Pipeline Candidate

• CT-179: A first-in-class, highly targeted, potent small molecule inhibitor of OLIG2.

Stages of Development

• Preclinical Stage: Completed preclinical studies demonstrating efficacy in animal models.

• Clinical Trials: An Investigational New Drug (IND) application is planned for the first half of 2022.

Target Conditions

• Glioblastoma (GBM): Affecting adults.

• Medulloblastoma (MB): Affecting children.

Anticipated Milestones

• IND Application Filing: Planned for the first half of 2022.

• Initiation of Clinical Trials: Expected in the first half of 2022.

Technological Platform and Innovation

Proprietary Technologies

• OLIG2 Inhibition: Developing small molecule inhibitors targeting the OLIG2 transcription factor to prevent tumor initiation and growth.

Significant Scientific Methods

• Pharmacophore-Based Small Molecule Design: Utilizing a novel combined pharmacophore-based small molecule design methodology to discover candidate compounds.

Leadership Team

Executive Profiles

• Gregory Stein, M.D., M.B.A.: Chief Executive Officer. Co-founder with extensive experience in the pharmaceutical industry, focusing on the development of new molecular entities for cancer and CNS disorders.

• David M. Weiner, M.D.: Chief Medical Officer. Provides medical oversight and strategic direction for clinical development.

• Michelle Rose, Ph.D.: Vice President, Regulatory Affairs. Oversees regulatory strategy and submissions.

• Lawrence J. Trost, Ph.D., DABT: Vice President, Toxicology & Nonclinical Development. Manages nonclinical safety assessments.

• Mark Sorenson, Ph.D.: Head, CMC Development. Leads chemistry, manufacturing, and controls development.

• Daniel Pertschuk, M.D.: Consultant, Clinical Development. Advises on clinical trial design and execution.

Competitor Profile

Market Insights and Dynamics

• Market Size: The global market for brain cancer therapeutics is substantial, with glioblastoma alone representing a market valued at approximately $380 million annually in the U.S. and around $1 billion worldwide.

• Growth Potential: With limited effective treatments available, there is significant potential for innovative therapies targeting cancer stem cells.

Competitor Analysis

• Lisata Therapeutics: Focuses on developing therapies for rare cancers, including brain tumors.

• Rapt Therapeutics: Develops oral therapies for cancer and autoimmune diseases.

• Edison Oncology: Specializes in precision oncology treatments.

Strategic Collaborations and Partnerships

• Catalent: Entered into a development and manufacturing agreement to support tablet formulation and manufacturing of CT-179.

Operational Insights

• Strategic Considerations: Curtana's focus on targeting cancer stem cells in the central nervous system differentiates it from competitors.

• Competitive Advantages: The proprietary OLIG2 inhibition platform offers a novel approach to treating aggressive brain cancers.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Clinical Development: Advance CT-179 through clinical trials to establish its safety and efficacy.

• Regulatory Approvals: Obtain necessary approvals to bring CT-179 to market.

Future Business Directions

• Expansion into Other CNS Tumors: Explore the potential of CT-179 in treating other central nervous system tumors.

• Partnerships: Seek additional strategic partnerships to enhance development capabilities.

Opportunities for Expansion

• Global Markets: Expand the reach of CT-179 to international markets with high unmet needs.

• Combination Therapies: Investigate the use of CT-179 in combination with other treatments to improve outcomes.

Contact Information

• Website: www.curtanapharma.com

• LinkedIn: Curtana Pharmaceuticals